IMMX vs ITG Comparison

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

ITG Inc provides services to the digital and other utility infrastructure industries throughout the United States. Its services support the planning, design, construction, operation, maintenance, and expansion of broadband and other infrastructure networks. It operates through two complementary service lines: i) Engineering & Maintenance: It provides re-occurring, mission-critical services required by network owners to operate, maintain, optimize and expand their infrastructure. ii) Infrastructure Deployment. It provides large-scale network and fiber construction services for incumbent carriers, overbuilders, and data center operators and underground civil construction services for public and private utilities. The majority of revenue is derived from the Engineering & Maintenance services.